Rifampin Pregnancy and Breastfeeding Warnings
Rifampin Pregnancy Warnings
FDA pregnancy category: C Potential benefit should outweigh the potential risk.
Animal studies have revealed evidence of embryotoxicity and teratogenicity. Congenital malformations (mainly spina bifida) were increased in the offspring of rats given rifampin during organogenesis at oral doses about 1 to 2 times the maximum recommended human dose (based on body surface area comparisons). Cleft palate was increased in fetuses of mice given oral doses about 0.2 to 0.8 times the maximum recommended human dose (based on body surface area comparisons). Imperfect osteogenesis and embryotoxicity were reported in rabbits given oral doses up to about 3 times the maximum recommended human dose (based on body surface area comparisons). There are no controlled data in human pregnancy. Rifampin crosses the human placenta and appears in cord blood. Data reveal a fetal:maternal serum concentration ratio of 0.23. Reports of the use of rifampin during pregnancy generally involve multiple drug therapy. In a review of 204 pregnancies during which exposure to rifampin occurred, 7 malformations were thought to be due to drug therapy, including anencephaly (1 case), hydrocephalus (2 cases), limb malformations (3 cases), and renal tract abnormalities (1 case). Postnatal hemorrhages in the mother and infant have been associated with the use of rifampin during the last few weeks of pregnancy; administration of vitamin K may be indicated. The initial therapy of active tuberculosis in pregnant patients recommended by the Centers for Disease Control includes rifampin. Rifampin is also recommended by the American Thoracic Society. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Rifampin Breastfeeding Warnings
Rifampin is excreted into human milk. Due to the potential for serious adverse effects in nursing infants, the decision should be made to either discontinue nursing or discontinue the drug based on the importance of the therapy to the mother.
References for pregnancy information
- Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.